|Dr. Niels Iversen Moeller M.D.||Co-Founder, VP of Bus. & Director||268k||N/A||1979|
|Mr. Andreas Holm Mattsson||Co-Founder and Chief AI & Culture Officer||290k||N/A||1976|
|Dr. Birgitte Rono Ph.D.||Chief Scientific Officer||309k||N/A||1976|
|Dr. Erik Deichmann Heegaard DMSC, M.D., Ph.D.||Chief Medical Officer||532k||N/A||1968|
|Dr. Per Norlen||Chief Exec. Officer||N/A||N/A||1970|
|Mr. Bo Lokke Karmark||Chief Financial Officer||N/A||N/A||1965|
|Mr. Jesper Nyegaard Nissen||Chief Operating Officer||N/A||N/A||1970|
|Dr. Jürgen Langhärig EMBA, Ph.D.||Head of Bus. Devel. & Member of Advisory Board||N/A||N/A||N/A|
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Evaxion Biotech A/S’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.